Molecular and cell signaling targets for PTSD pathophysiology and pharmacotherapy

NEUROPHARMACOLOGY

卷:62

Review

Hauger, Richard L.^1,2  Alberto Olivares-Reyes, J.³  Dautzenberg, Frank M.⁴  Lohr, James B.^1,2  Braun, Sandra¹  Oakley, Robert H.⁵ 

[1] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA

[2] VA Healthcare Syst, Ctr Excellence Stress & Mental Hlth, San Diego, CA 92161 USA

[3] Natl Polytech Inst CINVESTAV IPN, Ctr Res & Adv Studies, Dept Biochem, Mexico City 07360, DF, Mexico

[4] Nycomed GmbH, D-78467 Constance, Germany

[5] NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA

关键词: beta arrestin;    Biased agonist;    CRF receptor;    GRK;   

DOI  :  10.1016/j.neuropharm.2011.11.007

来源: Elsevier

【 摘 要 】

The reasons for differences in vulnerability or resilience to the development of posttraumatic stress disorder (PTSD) are unclear. Here we review key genetic diatheses and molecular targets especially signaling pathways that mediate responses to trauma and severe stress and their potential contribution to the etiology of PTSD. Sensitization of glucocorticoid receptor (GR) signaling and dysregulation of GR modulators FKBP5, STAT5B, Bcl-2, and Bax have been implicated in PTSD pathophysiology. Furthermore, Akt, NF kappa B, MKP-1, and p11, which are G protein-coupled receptor (GPCR) pathway molecules, can promote or prevent sustained high anxiety- and depressive-like behavior following severe stress. Agonist-induced activation of the corticotropin releasing factor CRF1 receptor is crucial for survival in the context of serious danger or trauma, but persistent CRF1 receptor hypersignaling when a threatening or traumatic situation is no longer present is maladaptive. CRF1 receptor single nucleotide polymorphisms (SNPs) can confer susceptibility or resilience to childhood trauma while a SNP for the PAC1 receptor, another class B1 GPCR, has been linked genetically to PTSD. GRK3 phosphorylation of the CRF1 receptor protein and subsequent binding of beta arrestin2 rapidly terminate Gs-coupled CRF1 receptor signaling by homologous desensitization. A deficient GRK-beta arrestin2 mechanism would result in excessive CRF1 receptor signaling thereby contributing to PTSD and co-morbid posttraumatic depression. Clinical trials are needed to assess if small molecule CRF1 receptor antagonists are effective prophylactic agents when administered immediately after trauma. beta arrestin2-biased agonists for CRF receptors and possibly other GPCRs implicated in PTSD, however, may prove to be novel pharmacotherapy with greater selectivity and therapeutic efficacy. This article is part of a Special Issue entitled 'Post-Traumatic Stress Disorder'. (C) 2011 Elsevier Ltd. All rights reserved.

【 授权许可】

Free